Oruka Therapeutics (ORKA) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Alpha Teknova (TKNO) over the past year, gaining 227.1% versus a gain of 77.4%. Over five years, ORKA leads with a +205.9% price change compared with -63.6% for TKNO. Oruka Therapeutics is the larger company by market cap ($6.50 billion vs $480.0 million), about 13.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | TKNO |
|---|---|---|
| Share price | $95.81 | $7.63 |
| Market cap | $6.50B | $479.95M |
| 1-day change | -1.80% | -2.30% |
| YTD return | +216.10% | +100.79% |
| 1-year return | +227.11% | +77.44% |
| 5-year return | +205.91% | -63.63% |
| EPS (TTM) | $-2.12 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $40.52M |
| Revenue growth (YoY) | — | +7.35% |
| Net income (latest FY) | $-105.43M | $-17.26M |
| Gross margin | — | 33.17% |
| Operating margin | — | -41.90% |
| Net margin | — | -42.59% |
| 52-week high | $115.52 | $9.48 |
| 52-week low | $25.23 | $1.91 |
| Distance from 52-week high | -17.06% | -19.51% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +63.00% | +28.83% |
| Average volume | 965.27K | 437.31K |
| Shares outstanding | 67.82M | 62.90M |
| Employees | 68 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 13.5 times larger than Alpha Teknova by market value ($6.50B vs $479.95M).
- ORKA has outperformed TKNO by 149.7 percentage points over the past year.
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
ORKA vs TKNO FAQ
Which is bigger, Oruka Therapeutics or Alpha Teknova?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $6.50B compared with $479.95M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, ORKA or TKNO?
ORKA returned +227.11% over the past 12 months, compared with +77.44% for TKNO (price return, excluding dividends). Past performance does not predict future results.
Are Oruka Therapeutics and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.